TERAPIA CELULAR Y MEDICINA REGENERATIVA
Hospital Miguel Servet
Zaragoza, EspañaPublicaciones en colaboración con investigadores/as de Hospital Miguel Servet (8)
2022
2021
-
Co-occurrence of cohesin complex and Ras signaling mutations during progression from myelodysplastic syndromes to secondary acute myeloid leukemia
Haematologica, Vol. 106, Núm. 8, pp. 2215-2223
-
Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations
British Journal of Haematology, Vol. 194, Núm. 4, pp. 708-717
2020
-
Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study
Leukemia, Vol. 34, Núm. 8, pp. 2125-2137
-
Early Prediction of Subsequent Molecular Response to Nilotinib in Patients with Chronic Myeloid Leukemia: Comparison of the Quantification of BCR-ABL1 Ratios Using ABL1 or GUSB Control Genes
Journal of Molecular Diagnostics, Vol. 22, Núm. 10, pp. 1217-1224
2012
-
Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: Are they present at diagnosis or are they induced by lenalidomide?
Haematologica, Vol. 97, Núm. 10, pp. 1608-1611
2011
-
Azacytidine for the treatment of myelodysplastic syndromes in the elderly
Advances in Therapy, Vol. 28, Núm. SUPPL. 2, pp. 10-15
-
Evaluation of tolerability and efficacy of imatinib mesylate in elderly patients with chronic phase CML: ELDERGLI study
Leukemia Research, Vol. 35, Núm. 9, pp. 1184-1187